We are glad to recommend two new drugs for #COVID19, providing yet more options for treating the disease. However, the global impact of these new medicines depends on how widely available and affordable they will be. For COVID patients, it can improve survival rates and reduce the need for ventilation in severely ill patients. Use of sotrovimab drugFor use of a monoclonal antibody sotrovimab, WHO has made a conditional recommendation for non-severe cases. "Today's recommendations are based on new evidence from seven trials involving over 4,000 patients with non-severe, severe, and critical covid-19 infection," WHO said in the British Medical Journal, reported Sputnik.

Source: Mint January 14, 2022 18:08 UTC